摘要 |
<p>Compounds of the general formula <EMI ID=1.1 HE=35 WI=45 LX=701 LY=119 TI=CF> <BR> <PC>wherein<BR> R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;<BR> R<SP>1</SP> is hydrogen or halogen; or<BR> R and R<SP>1</SP> may be together -CH=CH-CH=CH-;<BR> R<SP>2</SP> and R<SP>2'</SP> are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or<BR> R<SP>2</SP> and R<SP>2'</SP> may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy;<BR> R<SP>3</SP> is hydrogen, lower alkyl or form a cycloalkyl group;<BR> R<SP>4</SP> is hydrogen, -N(R<SP>5</SP>)<SB>2</SB>, -N(R<SP>5</SP>)(CH<SB>2</SB>)<SB>n</SB>OH, -N(R<SP>5</SP>)S(O)<SB>2</SB>-lower alkyl, -N(R<SP>5</SP>)S(O)<SB>2</SB>-phenyl, -N=CH-N(R<SP>5</SP>)<SB>2</SB>, -N(R<SP>5</SP>)C(O)R<SP>5</SP> or a cyclic tertiary amine of the group <EMI ID=1.2 HE=27 WI=40 LX=667 LY=1284 TI=CF> <BR> <PC>R<SP>5</SP> is, independently from each other, hydrogen, C<SB>3</SB>-<SB>6</SB>-cycloalkyl, benzyl or lower alkyl;<BR> R<SP>6</SP> is hydrogen, hydroxy, lower alkyl, -(CH<SB>2</SB>)<SB>n</SB>COO-lower alkyl, -N(R<SP>5</SP>)CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH<SB>2</SB>)<SB>n</SB>O(CH Þ )<SB>n</SB>OH, -CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group,<BR> X is -C(O)N(R<SP>5</SP>)-, -(CH<SB>2</SB>)<SB>m</SB>O-, -(CH<SB>2</SB>)<SB>m</SB>N(R<SP>5</SP>)-, -N(R<SP>5</SP>)C(O)-, or -N(R<SP>5</SP>)(CH<SB>2</SB>)m-;<BR> n is 0 - 4; and<BR> m is 1 or 2;<BR> and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK-1 receptor. They may be used for the treatment of diseases, which relate to NK-1 receptor antagonists.</p> |